The cytochrome P450 enzyme gene, CYP2C8, a member of the CYP gene family, participates in the proliferation, migration, invasion, and sorafenib resistance of HCC [41], indicating that CYP2C8 could be a potential target for the treatment of HCC. This evidence concerns the gene PPIG and hepatocellular carcinoma.